

Quantitative Ultrasound Visualization of Cell Death: Emerging Clinical Applications for Detection of Cancer Treatment Response*

Ali Sadeghi-Naini, *Member, IEEE*, Omar Falou, *Member, IEEE*, and Gregory J. Czarnota

Abstract— Differentiable echogeneities exhibited by living and dead cells enables the monitoring of cell death response via quantitative ultrasound techniques at high-frequencies and recently at clinical range frequencies. Such capability can be potentially employed to provide rapid and quantitative functional information in real time, and at the patient bedside for evaluating therapy response early following treatment. This paper summarizes backgrounds on quantitative ultrasound visualization of cell death and highlights its potential capabilities for monitoring cancer treatment response, where favorable results have been reported, according to a recent pilot clinical study.

I. INTRODUCTION

Cell death introduces structural changes in the cell's nucleus including nuclear condensation and fragmentation. We have previously demonstrated that nuclear structure is closely linked to ultrasound backscatter properties of cells and tissues for high frequency ultrasound. The changes in nuclear structure associated with cell death hence results in differentiable echogenicities of living cells, necrotic cells and cells dying of programmed cell death or apoptosis. This has been confirmed through several studies conducted, *in vitro*, *in situ*, *ex vivo*, and *in vivo* [1–10].

Ultrasound (US) radiofrequency (RF) signals carry information about tissue echogenicity but until recently have not been readily accessible on commercial ultrasound systems. Since a large number of instrument parameters are involved in a typical ultrasound imaging and data acquisition

session, it is difficult to establish a reasonable comparison between imaging data acquired by different standard ultrasound machines, or even by the same machine when different settings are used. Quantitative ultrasound methods have been proposed to address this shortcoming. Quantitative ultrasound analyzes the acquired raw-data before it is envelope detected, log-amplified and processed to form B-mode ultrasound image and employs calibration techniques to provide parameter estimates which are predominantly independent of instrument settings. Such estimates are frequently based on backscatter analysis of RF echoes and include the integrated backscatter, RF envelope statistics, frequency dependence of the backscatter, ultrasound tissue attenuation, and in a broader sense can include elastic properties of tissues, propagation of shear waves in tissues, and other signal classification techniques such as entropy metrics of RF ultrasonic backscatter [11], [12]. Different subsets of these parameters have been utilized in a number of clinically related applications, and particularly for tissue classification purposes, such as differentiating benign versus malignant disease [13–20].

II. QUANTITATIVE ULTRASOUND AND CELL DEATH

The application of quantitative ultrasound techniques for the detection of cell death is a relatively new development [21], [22]. High-frequency (20-60 MHz) quantitative ultrasound parameters have been found in preclinical animal tumour experiments to demonstrate reproducible and statistically significant features in the ultrasound signals that are associated with cell death. The methods are robust and can be applied to detecting and determining the extent of cell death from different anticancer therapies [1], [5], [10]. This is because high-frequency ultrasound is particularly sensitive to the structural changes that cells and tissues undergo during treatment response [3], [7], [9]. Such changes including nuclear condensation and fragmentation frequently result in substantial increases in tissue echogeneity, and consequently cause a large boost in backscatter signal. Other factors such as cell shape may also contribute, but the nuclear changes associated with cell death have been demonstrated to be responsible for the contrast in quantitative ultrasound

* This research has been supported by the Terry Fox Foundation, Canadian Institutes of Health Research (CIHR), and Canadian Breast Cancer Foundation (CBCF).

A. Sadeghi-Naini is with the Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, ON, Canada; also with Departments of Imaging Research and Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada (e-mail: Ali.Sadeghi-Naini@sunnybrook.ca).

O. Falou is with the Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, ON, Canada; also with Departments of Imaging Research and Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada (e-mail: Omar.Falou@sunnybrook.ca).

G. J. Czarnota is with the Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, ON, Canada; also with Departments of Imaging Research and Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada (phone: 416-480-6128; fax: 416-480-6002; e-mail: Gregory.Czarnota@sunnybrook.ca).




Figure 1: The application of conventional frequency quantitative US for monitoring tumour cell death response. (a), (b): Representative parametric 0-MHz intercept images of a large tumour during neo-adjuvant chemotherapy for a (a): clinically responding patient, (b): clinically non-responding patient. (c), (d): Quantitative 0-MHz intercept data averaged over the tumour area for the (c): clinically responding patient, (d): clinically non-responding patient. Scans 1, 2, 3, and 4 are pre-treatment, week 1, week 4, and week 8 scans, respectively. At scan 3 (4 weeks) of the clinically responding patient an increase in intercept is apparent compared to scan 1 (pre-treatment). In the case of the clinically non-responding patient there is no striking change in the 0-MHz intercept during the majority of therapy compared to the case of clinically responding patient. (e): The whole mount pathology corresponding to the clinically responding patient indicates a small residual mass in the mastectomy specimen (10 cm wide). (f): The whole mount pathology corresponding to the clinically non-responding patient indicates a large compact residual mass in the mastectomy specimen (8 cm wide).

parameters. However, whereas high-frequency ultrasound provides better lateral and axial resolutions (tens of microns), its clinical application is restricted due to a limited depth of ultrasound penetration [23]. Conventional (low) to mid-range ultrasound frequencies (1-20 MHz) have much deeper penetration and are hence broadly used in medicine, and very recently are being used to monitor cell death response to cancer treatment with quantitative ultrasound methods, as described in section III.

Whereas the detection of tissue changes related to necrosis using ultrasound methods were measured nearly fifty years ago, it is only very recently that quantitative methods have been applied using clinical US frequencies. In a set of recent studies, conventional ultrasound (3 to 10 MHz, -6 dB bandwidth) was used for real time detection of cell death using well controlled AML cell culture experiments. Results demonstrated an ability to detect as little as 10% apoptotic cells using ultrasound frequencies in the 10MHz range, paralleling changes observed using high-frequency ultrasound [1], [22]. Time-course experiments indicate that changes are detectable as early as 6 hours after exposure to chemotherapy drugs. These findings have been confirmed *in vivo* using prostate cancer PC3 tumour xenografts in mice [22], [24]. Here, large macroscopic areas of cell death were induced by novel anti-angiogenic agents in combination with radiation. One may argue that measurable backscatter changes from micron-sized particles are not expected at low-frequencies, mainly due to loss of scattering strength of small scattering structures. However, in the low-to-mid- frequency range, bulk changes in tissue are mostly related to ensembles of cells and nuclei smaller than the wavelength of the ultrasound being used. Such ensembles influence acoustic properties and thus ultrasound backscatter. The potential scatterers are closer in size to those that predominate in the Rayleigh scattering regime, as they are about 10 times smaller than the interrogating wavelength. In addition, when imaging cell samples, even at these low frequencies, a speckle pattern is still formed indicating that many sub-resolution scatterers contribute to the detected signals. Results based on experiments using over 50 animals assessed with high-frequency and conventional frequency ultrasound suggests that the monitoring of treatment efficacy is possible using low-frequency ultrasound.

III. EMERGING CLINICAL APPLICATIONS

In a pilot clinical study, quantitative ultrasound at conventional frequencies has been applied for evaluation of tumour cell death response in locally advanced breast cancer patients receiving neo-adjuvant chemotherapy [25].

Conventional 7 to 10 MHz US data were acquired prior to treatment onset and at 4 times during treatment. In each session, several scan planes with the size of 6 by 4 cm were acquired from the same nominal regions. The RF signal's power spectrums were normalized, as before [1], [4], [7], at each region of interest (ROI) using a reference's power spectrum obtained from an agar-embedded glass-bead phantom model, at the same ROI position. The results (n=10 patients) demonstrated a close association between quantitative ultrasound changes after one to two cycles of chemotherapy (weeks) and clinical response in the tumour many months later. More specifically, patients who had a significant clinical response demonstrated changes in quantitative ultrasound parameters consistent with cell death, while women with no changes in quantitative ultrasound parameters demonstrated no ultimate clinical response (Figure 1). The promising results emerging from this study pave the way for establishing protocols for the clinical applications of the conventional frequency quantitative ultrasound techniques in therapy response monitoring. As such, quantitative ultrasound at conventional frequencies is expected to provide rapid and quantitative functional information in real time for evaluating responses to a specific therapy in the near future.

REFERENCES

- [1] B. Banihashemi, R. Vlad, B. Debeljevic, A. Giles, M. C. Kolios, and G. J. Czarnota, "Ultrasound imaging of apoptosis in tumor response: novel preclinical monitoring of photodynamic therapy effects," *Cancer research*, vol. 68, no. 20, pp. 8590-6, Oct. 2008.
- [2] G. J. Czarnota et al., "Ultrasonic biomicroscopy of viable, dead and apoptotic cells," *Ultrasound in medicine & biology*, vol. 23, no. 6, pp. 961-5, Jan. 1997.
- [3] G. J. Czarnota et al., "Ultrasound imaging of apoptosis: high-resolution non-invasive monitoring of programmed cell death in vitro, in situ and in vivo," *British journal of cancer*, vol. 81, no. 3, pp. 520-7, Oct. 1999.
- [4] L. R. Taggart, R. E. Baddour, A. Giles, G. J. Czarnota, and M. C. Kolios, "Ultrasonic characterization of whole cells and isolated nuclei," *Ultrasound in medicine & biology*, vol. 33, no. 3, pp. 389-401, Mar. 2007.
- [5] A. S. Tunis, G. J. Czarnota, A. Giles, M. D. Sherar, J. W. Hunt, and M. C. Kolios, "Monitoring structural changes in cells with high-frequency ultrasound signal statistics," *Ultrasound in medicine & biology*, vol. 31, no. 8, pp. 1041-9, Aug. 2005.
- [6] M. C. Kolios, G. J. Czarnota, M. Lee, J. W. Hunt, and M. D. Sherar, "Ultrasonic spectral parameter characterization of apoptosis," *Ultrasound in medicine & biology*, vol. 28, no. 5, pp. 589-97, May 2002.
- [7] R. M. Vlad, N. M. Alajez, A. Giles, M. C. Kolios, and G. J. Czarnota, "Quantitative ultrasound characterization of cancer radiotherapy effects in vitro," *International journal of radiation oncology, biology, physics*, vol. 72, no. 4, pp. 1236-43, Nov. 2008.

- [8] S. Brand, B. Solanki, D. B. Foster, G. J. Czarnota, and M. C. Kolios, "Monitoring of cell death in epithelial cells using high frequency ultrasound spectroscopy," *Ultrasound in medicine & biology*, vol. 35, no. 3, pp. 482-93, Mar. 2009.
- [9] R. M. Vlad, G. J. Czarnota, A. Giles, M. D. Sherar, J. W. Hunt, and M. C. Kolios, "High-frequency ultrasound for monitoring changes in liver tissue during preservation," *Physics in medicine and biology*, vol. 50, no. 2, pp. 197-213, Jan. 2005.
- [10] R. M. Vlad, S. Brand, A. Giles, M. C. Kolios, and G. J. Czarnota, "Quantitative ultrasound characterization of responses to radiotherapy in cancer mouse models," *Clinical cancer research*, vol. 15, no. 6, pp. 2067-75, Mar. 2009.
- [11] M. S. Hughes et al., "Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo," *IEEE transactions on ultrasonics, ferroelectrics, and frequency control*, vol. 53, no. 9, pp. 1609-16, Sep. 2006.
- [12] K. Wallace et al., "Sensitive Ultrasonic Delineation of Steroid Treatment in Living Dystrophic Mice with Energy-Based and Entropy-Based Radio Frequency Signal Processing," *IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control*, vol. 54, no. 11, pp. 2291-2299, Nov. 2007.
- [13] A. Guimond et al., "Quantitative ultrasonic tissue characterization as a new tool for continuous monitoring of chronic liver remodelling in mice," *Liver international*, vol. 27, no. 6, pp. 854-64, Aug. 2007.
- [14] M. Yang, T. M. Krueger, J. G. Miller, and M. R. Holland, "Characterization of anisotropic myocardial backscatter using spectral slope, intercept and midband fit parameters," *Ultrasonic imaging*, vol. 29, no. 2, pp. 122-34, Apr. 2007.
- [15] Z. Vered et al., "Quantitative ultrasonic tissue characterization with real-time integrated backscatter imaging in normal human subjects and in patients with dilated cardiomyopathy," *Circulation*, vol. 76, no. 5, pp. 1067-73, Nov. 1987.
- [16] J. W. Allison, L. L. Barr, R. J. Massoth, G. P. Berg, B. H. Krasner, and B. S. Garra, "Understanding the process of quantitative ultrasonic tissue characterization," *Radiographics*, vol. 14, no. 5, pp. 1099-108, Sep. 1994.
- [17] S. Takiuchi et al., "Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries," *Circulation*, vol. 102, no. 7, pp. 766-70, Aug. 2000.
- [18] A. Kovacs et al., "Ultrasonic tissue characterization of the mouse myocardium: successful in vivo cyclic variation measurements," *Journal of the American Society of Echocardiography*, vol. 17, no. 8, pp. 883-92, Aug. 2004.
- [19] M. L. Oelze, W. D. O'Brien, J. P. Blue, and J. F. Zachary, "Differentiation and characterization of rat mammary fibroadenomas and 4T1 mouse carcinomas using quantitative ultrasound imaging," *IEEE transactions on medical imaging*, vol. 23, no. 6, pp. 764-71, Jun. 2004.
- [20] J. Mamou, M. L. Oelze, W. D. O'Brien, and J. F. Zachary, "Identifying ultrasonic scattering sites from three-dimensional impedance maps," *The Journal of the Acoustical Society of America*, vol. 117, no. 1, pp. 413-23, Jan. 2005.
- [21] G. J. Czarnota and M. C. Kolios, "Ultrasound detection of cell death," *Imaging in Medicine*, vol. 2, no. 1, pp. 17-28, Feb. 2010.
- [22] M. C. Kolios and G. J. Czarnota, "Potential use of ultrasound for the detection of cell changes in cancer treatment," *Future oncology*, vol. 5, no. 10, pp. 1527-32, Dec. 2009.
- [23] F. S. Foster, C. J. Pavlin, K. A. Harasiewicz, D. A. Christopher, and D. H. Turnbull, "Advances in ultrasound biomicroscopy," *Ultrasound in medicine & biology*, vol. 26, no. 1, pp. 1-27, Jan. 2000.
- [24] J. Lee et al., "Novel low-frequency ultrasound detection of apoptosis in vitro and in vivo," in *American Association of Cancer Research Annual Meeting*, 2008, p. LB-295.
- [25] N. Papanicolau et al., "Conventional frequency evaluation of tumor cell death response in locally advanced breast cancer patients to chemotherapy treatment administration," *Journal of the Acoustical Society of America*, vol. 128, no. 4, p. 2365, 2010.